IMNN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

IMNN ▲ +2.04% at T+20d

NEUTRAL call ✓ call won +2.04% · α vs SPY -6.86% · entry $2.94 → $3.00

Next anchor: T+60d in 5d

Currently $2.02 · -31.29% from $2.94 entry

Entry anchored
Mar 23, 03:59 PM ET
via Databento tick

T+1d

-5.44%

call -5.44% · α -6.01%

$2.78

settled 3mo ago

T+5d

0.00%

call 0.00% · α +0.42%

$2.94

settled 2mo ago

T+20d

+2.04%

call +2.04% · α -6.86%

$3.00

settled 7w ago

T+60d

—

call — · α —

—

in 5d

Price Chart

Loading chart...

Executive Summary

Imunon, Inc. announced it will host a conference call on March 31, 2026, to discuss its 2025 financial results and provide a clinical update on its lead candidate, IMNN-001, currently in Phase 3 for advanced ovarian cancer. No actual financial data was released in this press release, only the announcement of an upcoming earnings call.

Actionable Insight

Traders should monitor the March 31 conference call for actual financial results and any updates on clinical trial progress, especially enrollment status in OVATION 3, which could influence investor sentiment.

Key Facts

Imunon will host a conference call on March 31, 2026, at 11:00 a.m. EDT to discuss 2025 financial results and clinical updates.
No financial results or clinical data were disclosed in this press release.
The company is advancing IMNN-001, a DNA-based IL-12 immunotherapy, in a Phase 3 trial (OVATION 3) for advanced ovarian cancer.
Dosing completed in a first-in-human study of its COVID-19 booster vaccine, IMNN-101.

Financial Impact

None disclosed — financial results not released

Risk Factors

No material data provided in this release — potential for disappointment if upcoming results are weak.
Clinical-stage biotech risk: Phase 3 trial outcomes are uncertain and subject to failure despite prior Phase 2 data.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3261137

5 reports for IMNN

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IMNN — sortable, filterable
	Type				Now
Jun 4, 2026 8d ago	8-K BEARISH ★ 6/10	$2.10 $2.06	▲ +1.90%	▼ −0.69%	$2.02 (+3.81%)
May 12, 2026 4w ago	8-K BULLISH ★ 6/10	$2.70 $2.60	▼ −3.70%	▼ −4.28%	$2.02 (−25.19%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 2/10	$2.80 $2.77	▼ −1.07%	▼ −1.87%	$2.02 (−27.86%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$2.94 $2.99	▲ +1.70%	▲ +0.95%	$2.02 (−31.29%)
Mar 24, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$2.94 $2.78	▼ −5.44%	▼ −6.01%	$2.02 (−31.29%)

US Market Status

Market Closed — Opens Mon (49h 42m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access